CTI BioPharma (CTIC) has an average broker rating of 3.67, which is interpreted as a Sell, as rated by 3 equity analysts. Nevertheless, the majority of 2 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold. 1 brokerage firm advices Strong Sell on the share due to lack of confidence about the future of the company.
Company shares have received an average consensus rating of Hold for the current week
CTI BioPharma (NASDAQ:CTIC): The stock opened at $0.3922 and touched an intraday high of $0.42 on Wednesday. During the day, the stock corrected to an intraday low of $0.3922, however, the bulls stepped in and pushed the price higher to close in the green at $0.3929 with a gain of 0.10% for the day. The total traded volume for the day was 1,088,978. The stock had closed at $0.3925 in the previous trading session.
CTI BioPharma Corp. (CTI), formerly Cell Therapeutics, Inc., is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers that offer a benefit to patients and healthcare providers. The Company is focused on commercializing PIXUVRI (pixantrone), or PIXUVRI, in the European Union, for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL), and conducting a Phase III clinical trial program of pacritinib for the treatment of adult patients with myelofibrosis to support regulatory submission for approval in the United States and Europe. It is also engaged in evaluating pacritinib in earlier clinical trials as treatment for other blood-related cancers. Its development product candidates include tosedostat and Opaxio.